顺尔宁联合信必可都保对老年稳定期慢性阻塞性肺疾病患者的应用效果分析

Analysis of the Efficacy of Singulair in Combination with Symbicort in Elderly Patients with Stable COPD

目的:探讨顺尔宁联合信必可都保对老年稳定期慢性阻塞性肺疾病(COPD)的应用效果。方法:前瞻性选取2019年1月至2021年5月期间我院收治的198例老年稳定期COPD患者为研究对象,采用简单随机分组将全部患者均分为A、B、C三组,分别在常规对症处理的基础上给予顺尔宁(孟鲁司特钠片)、信必可都保(布地奈德福莫特罗吸入剂)、顺尔宁+信必可都保,持续12周。比较三组干预前后的呼吸功能、炎症反应、疾病控制状况、临床疗效及不良反应发生率。结果:三组干预后的FEV1、FVC、FEV1/FVC比值、PaO_(2)均显著高于干预前,PaCO_(2)、痰液中性粒细胞、嗜酸性粒细胞比例、IL-8、MPO水平、CAT问卷总分显著低于干预前(P<0.05)。组间比较,C组FEV1、FVC、FEV1/FVC、PaO_(2)、PaCO_(2)、痰液中性粒细胞、嗜酸性粒细胞比例、IL-8、MPO水平、CAT问卷总分干预前后的差值均显著高于同期A组与B组,B组FEV1/FVC、PaO_(2)、PaCO_(2)、痰液中性粒细胞比例、IL-8、MPO水平干预前后的差值均显著高于同期A组(P<0.017)。C组的总有效率达到95.5%,均显著高于A组的74.2%、B组的80.3%(P<0.017)。全部患者均未出现肝肾功能损伤、心律失常、骨骼肌震颤等严重并发症,三组患者各并发症发生率比较,差异无统计学意义(P>0.05),且给予对症处理后均痊愈,未影响治疗进程。结论:顺尔宁联合信必可都保能显著改善老年COPD稳定期患者的症状、呼吸功能与气道炎症,安全有效,值得临床推广应用。

Objective:To investigate the effect of Singulair combined with Symbicort on elderly patients with stable chronic obstructive pulmonary disease(COPD).Methods:Prospectively,198 elderly patients with stable COPD admitted to our hospital between January 2019 and May 2021 were selected for the study,and all patients were divided into groups A,B and C using simple random grouping,and were given cisplatin(montelukast sodium tablets),cisplatin duplex(budesonide formoterol inhaler),cisplatin+cisplatin duplex,respectively,on the basis of conventional symptomatic management for 12 weeks.The respiratory function,inflammatory response,disease control status,clinical efficacy and incidence of adverse effects were compared before and after the intervention in the three groups.Results:In all three groups,FEV1,FVC,FEV1/FVC ratio and PaO_(2) were significantly higher than before the intervention,while PaCO_(2),sputum neutrophils,eosinophil ratio,IL-8,MPO level and total CAT questionnaire score were significantly lower than before the intervention(P<0.05).When comparing between groups,the differences in FEV1,FVC,FEV1/FVC,PaO_(2),PaCO_(2),sputum neutrophils,eosinophil ratio,IL-8,MPO level and total CAT questionnaire score before and after intervention were significantly higher in group C than in groups A and B during the same period,and the differences in FEV1/FVC,PaO_(2),PaCO_(2),sputum neutrophil ratio,IL-8,MPO level and total CAT questionnaire score before and after intervention were significantly higher in group B.The overall effective rate of group C was 95.5%,which was significantly higher than that of group A(74.2%)and group B(80.3%)(P<0.017).All patients did not suffer from serious complications such as liver and kidney function damage,cardiac arrhythmia and skeletal muscle tremor,etc.The difference in the incidence of each complication among the three groups was not statistically significant(P>0.05),and all patients recovered after symptomatic treatment without affecting the treatment process.Conclusion:Singulair combined with Symbicort could significantly improve the symptoms,respiratory function and airway inflammation of elderly patients with stable COPD,which is safe,effective and worthy of clinical application.